

TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

10/14/2013; Page 1

Suggested Formula	Azithromycin 200 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 004 074v2

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Azithromycin (250 mg) Tablets**	16	Units				
Glycerin, USP	20.0	mL				
Cherry Flavor (Artificial)	0.3	mL				
Banana Cream Flavor	0.5	mL				
Medisca Oral Suspend (Suspending Vehicle)	35.0	mL				
Medisca Oral Syrup (Flavored Vehicle)	q.s. to 100.0	mL	8			
Sodium Hydroxide 10% Solution	As required			Y		
Hydrochloric Acid 10% Solution	As required					

^{**}Delivered as Azithromycin Dihydrate.

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information	(2)/(0)								
Hygroscopic (protect from mo	Hygroscopic (protect from moisture whenever possible): Glycerin								
Suggested Preparatory Guidelines									
Non-Sterile Prepara	tion								
Processing Error / Testing Considerations:	To account for processing error and pH testing considerations during preparation, it is suggested to measure an additional 5 to 9% of the required quantities of ingredients.								
Special Instruction:	Protective apparel, such as a lab coat, disposable gloves, eyewear and face-masks should always be worn.								
	This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.								



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

10/14/2013; Page 2

Suggested Formula	Azithromycin 200 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 004 074v2
----------------------	---	-----	-------------

SUGGESTED PREPARATION (for 100 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*):	Processing Error	Qty. to measure
Azithromycin (250 mg) Tablets	16	Units			
Glycerin, USP §	20.0	mL			
Cherry Flavor (Artificial)	0.3	mL			
Banana Cream Flavor	0.5	mL	8		
Medisca Oral Suspend (Suspending Vehicle)	35.0	mL			
Medisca Oral Syrup (Flavored Vehicle)	q.s. to 100.0	mĹ			
Sodium Hydroxide 10% Solution	As required		1		
Hydrochloric Acid 10% Solution	As required				

- * Takes into account increased batch size conversions and density conversions, if required.
- § Weigh / measure just prior to use.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

10/14/2013; Page 3

16

g

	Preparatory Instruction		
Ing	gredient quantification (determine the actual quantity of Azithromycin (250 mg) table	et pow	der to weigh):
A.	Weigh 18 Azithromycin (250 mg) Tablets. Record the total weight here:	_	g
В.	Calculate the average weight of powder in each tablet:		
	Weight of 18 tablets (from Step 1A):	_	g
	DIVIDED BY		
	Number of tablets:		18
	EQUALS		
	Average weight of a single Azithromycin (250 mg) Tablet:	-	g
C.	Calculate the weight of powder equivalent to 16 tablets:		
C.	Calculate the weight of powder equivalent to 16 tablets:		
	Average weight of a single Azithromycin (250 mg) Tablet (from Step 1B):	-	
	MULTIPLED BY		

D. Calculate the weight of powder required *plus* processing error adjustments:

Number of tablets required:

Weight of powder equivalent to 16 tablets:

EQUALS

Weight of powder equivalent to 16 tablets (from Step 1C):	
MULTIPLED BY	
Processing error adjustments (5 to 9%):	1.05 to 1.09
EQUALS	

Weight of powder required plus processing error adjustments:



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

10/14/2013; Page 4

Suggested Formula	Azithromycin 200 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 004 074v2
----------------------	---	-----	-------------

2. **Powder preparation:**

- A. Crush and triturate the 18 Azithromycin (250 mg) Tablets into a fine homogeneous powder.
- B. Weigh the quantity of Azithromycin (250 mg) tablet powder mix required for the batch (refer to Step 1D) and discard the remaining powder.

3. **Powder-liquid preparation:**

A. Levigate the Azithromycin (250 mg) tablet powder mix (amount weighed in Step 2B) with the Glycerin.

End result: Homogeneous paste-like dispersion.

4. **Medium Integration:**

- A. In the given order, sequentially add the following ingredients to the Oral Suspend (Suspending Vehicle):
 - -Cherry Flavor (Artificial)
 - -Banana Cream Flavor
 - -Homogeneous paste-like dispersion (Step 3A)

Specifications: Continuously mix, using high-shear mixing techniques.

End result: Homogeneous liquid-like dispersion.

Note: Add the next ingredient, once the previous one has been completely added and dispersed.

5. **Filling to volume:**

A. Add Oral Syrup (Flavored Vehicle) to the mixture (Step 4A) to fill to the required batch size (100.0 mL *plus* processing error adjustments).

<u>Specifications</u>: Continuously mix, using high-shear mixing techniques.

End result: Homogeneous liquid-like dispersion.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

10/14/2013; Page 5

Suggested Formula	Azithromycin 200 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 004 074v2
----------------------	---	-----	-------------

6. **pH testing:**

- A. Draw an appropriate amount of the mixture (Step 5A).
- B. Test the pH of the sample. It should lie between 9 and 11.
- C. If the pH < 9, carefully add, in a dropwise fashion, the Sodium Hydroxide 10% Solution to the mixture:
 - 1. Draw and transfer 1 or 2 drops of the Sodium Hydroxide 10% Solution to the mixture.
 - 2. Stir for at least 5 minutes to evenly disperse the Sodium Hydroxide 10% Solution.
 - 3. Re-test the pH.
 - 4. Continue to add the Sodium Hydroxide 10% Solution until the pH of 9 to 11 is obtained.

IMPORTANT: Do not allow the pH to rise above 11.

- D. If the pH > 11, carefully add, in a dropwise fashion, the Hydrochloric Acid 10% Solution to the mixture:
 - 1. Draw and transfer 1 or 2 drops of the Hydrochloric Acid 10% Solution to the mixture.
 - 2. Stir for at least 5 minutes to evenly disperse the Hydrochloric Acid 10% Solution.
 - 3. Re-test the pH.
 - 4. Continue to add the Hydrochloric Acid 10% Solution until the pH of 9 to 11 is obtained.

IMPORTANT: Do not allow the pH to fall below 9.

7. **Product transfer:**

A. Transfer the final product into the specified dispensing container (see "Packaging requirements").

<u>Note</u>: Continuously mix the final product during the transfer process into the recommended dispensing containers in order to maintain homogeneity.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

10/14/2013; Page 6

Suggested Formula	Azithromycin 200 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 004 074v2
1 Officia			l

SUGGESTED PRESENTATION

GGESTED PRI	LJE	NIATION			
Estimated Beyond-Use Date		10 days, refrigerated.	Packa Requirem		 Tightly closed, light-resistant dispensing bottle. To be administered with a metered dose-measuring device.
	1	Use as directed. Do not exceed dose.	d prescribed	6	Shake well before use.
	2	Keep out of reach of children.		7	Protect from light.
Auxiliary Labels	3	Consult your health care practit prescription or over medications are currently being prescribed for future use.	-the-counter	8	Cap tightly after use.
	4	May impair mental and/or physuse care when operating machinery.		9	Do not take with alcohol, sleep aids, tranquilizers or other CNS depressants.
	5	Keep refrigerated. Do not freeze		N) '
Pharmacist Instructions	Ad	d any auxiliary labels specific to t	he API to the	dispe	nsing container as deemed necessary.
Patient Instructions	Со	ntact your pharmacist in the event	of adverse re	action	ns.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

10/14/2013; Page 7

Suggested Formula	Azithromycin 200 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 004 074v2
----------------------	---	-----	-------------

REFERENCES

1.	Suspensions. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding</i> . American Pharmaceutical Association; 2008: 209.	
2.	Zithromax. In: Canadian Pharmacists Association. Compendium of Pharmacists and Specialties, 2009. 2665.	
3.	Azithromycin. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36th Edition.</i> London, England: The Pharmaceutical Press; 2009: 207.	
4.	Azithromycin (Monograph). In: O'Neil MJ. <i>The Merck Index 14th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2006: 915.	
5.	Azithromycin (Monograph). <i>United States Pharmacopeia XXXII / National Formulary 27</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2009: 1613.	
6.	Azithromycin Systemic. Thomson Micromedex. <i>USP DI – Drug Information for the Health Care Professional</i> , 26 th <i>Edition</i> . Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 505.	
7.	USP <795>. <i>United States Pharmacopeia XXXII / National Formulary 27</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2009: 314.	

DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.